Gibson Oncology raised $1 million to advance LMP744, an FDA-designated orphan drug being evaluated in NIH-funded clinical trials for the treatment of glioblastoma, an aggressive and difficult-to-treat brain cancer.
Gibson Oncology raised $1 million to advance LMP744, an FDA-designated orphan drug being evaluated in NIH-funded clinical trials for the treatment of glioblastoma, an aggressive and difficult-to-treat brain cancer.